Drugs / CB-AC-02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02899091 | Sep 2016 → Dec 2024 | Alzheimer disease | CHABiotech CO., Ltd | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CB-AC-02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02899091 ↗ |
| Route | Intravenous | “intraveneously administered CB-AC-02” NCT02899091 ↗ |